60 Degrees Pharmaceuticals, Inc. (SXTPW) income statement

SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value

$0.03−0.00 (-0.38%)

Close on Oct 30, 2026Market cap $3.31MP/E –Yield –

60 Degrees Pharmaceuticals, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31
Revenue	1.11	1.00	1.01	0.94	0.64	0.67	0.61	0.49	0.41	0.34	0.25	–	–	–	–
Cost of Revenue	0.90	0.79	0.78	0.78	0.35	0.39	0.38	0.41	0.37	0.47	0.47	0.49	0.51	0.42	0.43
Gross Profit	0.22	0.21	0.22	0.16	0.29	0.27	0.22	0.08	0.04	-0.12	-0.22	–	–	–	–
Research & Development	2.33	1.96	2.11	2.03	2.16	5.02	4.99	4.47	3.80	0.90	0.69	0.80	0.56	0.59	0.53
General & Administrative	6.60	6.50	6.28	6.47	6.18	5.67	5.03	5.11	5.21	4.54	4.24	2.86	1.96	1.90	1.30
Operating Expenses	8.93	8.46	8.39	8.49	8.33	11	10	9.58	9.01	5.45	4.93	3.66	2.52	2.49	1.83
Operating Income	-8.61	-7.94	-7.76	-7.91	-7.70	-10	-9.72	-9.54	-8.95	-5.55	-5.15	-3.95	-2.64	-2.54	-1.75
Interest Expense	0.01	0.01	0.01	0.01	0.01	0.01	0.01	2.23	2.23	3.33	2.29	3.35	4.56	4.37	3.99
Other Non-Operating Income	0.37	0.37	0.39	1.77	1.75	1.76	1.76	0.05	-0.03	–	-0.08	–	–	–	-0.04
Pretax Income	-8.11	-7.58	-7.37	-7.98	-7.82	-10	-7.96	-7.95	-1.62	-0.79	-3.81	-3.44	-9.06	-7.87	-6.18
Income Tax Expense	–	–	0	0.00	0.00	0	0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income from Continuing Operations	–	–	–	–	–	–	–	–	0.07	-0.09	-0.22	-0.29	-0.12	-0.05	0.08
Net Income incl. Noncontrolling Interests	-8.11	-7.58	-7.37	-7.98	-7.82	-10	-7.96	-7.95	-1.62	-0.79	-3.81	-3.44	-9.06	-7.87	-6.18
Minority Interest in Earnings	0.00	0.00	0.00	-0.01	-0.01	-0.01	-0.01	-0.04	-0.05	-0.05	-0.05	-0.01	0.00	0.00	0.00
Net Income	-8.11	-7.58	-7.37	-7.97	-7.82	-10	-7.95	-7.91	-1.57	-0.74	-3.77	-3.43	-9.06	-7.87	-6.18
Preferred Dividends	1.72	1.71	1.21	1.21	1.20	1.19	0.70	–	–	–	–	–	–	–	–
Net Income to Common	-8.62	-8.06	-7.86	-8.47	-8.30	-11	-8.43	-8.33	-1.97	-1.01	-3.92	-3.50	-9.05	–	-6.18
EPS (Basic)(per share)	–	–	–	–	–	–	–	–	–	–	–	-592.02	-921.02	-814.62	-626.40
EPS (Diluted)(per share)	–	–	–	–	–	–	–	–	–	–	–	-592.02	-921.02	-814.62	-626.40
Shares Outstanding (Basic, Weighted)(shares)	1.59	1.02	0.67	–	–	–	–	0.06	0.03	0.02	0.02	0.01	0.01	0.01	0.01
Shares Outstanding (Diluted, Weighted)(shares)	1.59	1.02	0.67	–	–	–	–	0.16	0.03	0.02	0.02	0.01	0.01	0.01	0.01
EBITDA	-8.55	-7.89	-7.72	-7.87	-7.68	-10	-9.70	–	–	–	–	–	–	–	–
Net Interest Income	–	–	–	–	–	–	–	–	7.32	4.75	1.34	0.51	-6.42	-5.33	-4.43

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 19.4%
Operating margin: -774.9%
Net margin: -729.9%
Return on equity, FY2025: -196.4%

Financial strength

Current ratio: 2.32
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 63.7%

Valuation

P/E ratio: –
Price to sales: 2.98
Price to book: 1.26
Dividend yield: –